Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

AustriaBack to Austria

Clinical trials in Salzburg – page 22

285 clinical trials in Salzburg, Austria across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Salzburg at a glance
285
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

285 trials in Salzburg

Open in trial search

Colitis ulcerative

Not recruiting

Study on the Effects of GS-5290 for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(Phosphonooxy)Methyln-[(S)-[1-(Bicyclo[1.1.1]Pentan1-Yl)-1H-1,2,3-Triazol-4-Yl](2-Methyl-1-Oxo-1,2-Dihydroisoquinolin-5-Yl)Methyl]-N-{8-Chloro-3-Cyano-4-[(2,2-Dimethylpropyl)Amino]Quinolin-6-Yl]Carbamate
  • Sponsor:Gilead Sciences Inc.

Breast cancer metastatic+2

Not recruiting

Study of Patritumab Deruxtecan for Patients with Brain Metastases from Advanced Breast or Lung Cancer and Leptomeningeal Disease from Solid Tumors

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Medica Scientia Innovation Research S.L.

Oesophageal adenocarcinoma

Not recruiting

Study of Sacituzumab Govitecan for Patients with Advanced Esophagogastric Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Macular oedema+1

Not recruiting

Study on Ranibizumab Injections and Laser Treatment for Macular Edema in Central Retinal Vein Occlusion Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Justus-Liebig-Universitaet Giessen

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Myelodysplastic syndrome

Not recruiting

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colorectal cancer metastatic

Not recruiting

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Squamous cell carcinoma of head and neck

Not recruiting

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness and Safety of Oral Azacitidine for Patients with Low or Intermediate-Risk Myelodysplastic Syndrome

Not recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Celgene Corp.

Growth hormone deficiency

Not recruiting

Study on Growth Hormone Deficiency: Comparing Effects of Continuing vs. Stopping Somatropin Treatment in Pubertal Children with Isolated Growth Hormone Deficiency

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Somatropin
  • Sponsor:University College London

Netherton's syndrome

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab in Treating Patients with Netherton Syndrome

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Salzburg

What the registry says about research in the country

01 Oncology Research

Comprehensive studies focusing on metastatic cancers and innovative treatment approaches, including trials investigating new therapies for prostate cancer, colorectal cancer, and bladder cancer.

  • Advanced cancer treatments
  • Immunotherapy combinations
  • Novel therapeutic agents

Multiple clinical trials evaluating targeted therapies and combination treatments for various stages of cancer progression.

02 Hematological Studies

Investigating breakthrough treatments for multiple myeloma and acute myeloid leukemia, with emphasis on innovative therapeutic combinations and targeted approaches.

  • Blood cancer therapies
  • Novel drug combinations
  • Treatment resistance studies

Focus on improving outcomes for patients with various blood disorders through advanced therapeutic strategies.

03 Chronic Disease Management

Research initiatives addressing cardiovascular disease, Crohn's disease, and Alzheimer's disease, exploring new treatment modalities and therapeutic approaches.

  • Inflammatory conditions
  • Cardiovascular health
  • Neurological disorders

Comprehensive studies aimed at developing more effective treatments for chronic conditions affecting quality of life.

Back to AustriaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.